FKA‐A NPs enhances PTX‐A NPs efficacy to suppress ovarian cancer via regulating Skp2/YAP pathway
暂无分享,去创建一个
[1] Shuying Yang,et al. Verteporfin Inhibits the Progression of Spontaneous Osteosarcoma Caused by Trp53 and Rb1 Deficiency in Ctsk-Expressing Cells via Impeding Hippo Pathway , 2022, Cells.
[2] H. Asadzadeh Aghdaei,et al. Oncogenic Role of Connective Tissue Growth Factor Is Associated with Canonical TGF-β Cascade in Colorectal Cancer , 2022, Genes.
[3] Leiqiang Han,et al. Inflammatory molecules facilitate the development of docetaxel‐resistant prostate cancer cells in vitro and in vivo , 2022, Fundamental & clinical pharmacology.
[4] E. Arefian,et al. Wnt5A and TGFβ1 Converges through YAP1 Activity and Integrin Alpha v Up-Regulation Promoting Epithelial to Mesenchymal Transition in Ovarian Cancer Cells and Mesothelial Cell Activation , 2022, Cells.
[5] M. Paquet,et al. Statins downregulate YAP and TAZ and exert anti-cancer effects in canine mammary tumor cells. , 2021, Veterinary and comparative oncology.
[6] E. Maiello,et al. Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives , 2021, Cancers.
[7] Yi-ming Li,et al. Programmed cell death 10 promotes metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma via PP2Ac-mediated YAP activation , 2021, Cell Death & Disease.
[8] Yan Wang,et al. Imipramine impedes glioma progression by inhibiting YAP as a Hippo pathway independent manner and synergizes with temozolomide , 2021, Journal of cellular and molecular medicine.
[9] Z. Ji,et al. Bladder mesenchymal stromal cell-derived exosomal miRNA-217 modulates bladder cancer cell survival through Hippo-YAP pathway , 2021, Inflammation Research.
[10] Zhen-ning Wang,et al. Inhibitors Targeting YAP in Gastric Cancer: Current Status and Future Perspectives , 2021, Drug design, development and therapy.
[11] Xinsheng Gu,et al. Emerging Roles of SKP2 in Cancer Drug Resistance , 2021, Cells.
[12] J. Chi,et al. The Hippo Pathway Effector YAP Promotes Ferroptosis via the E3 Ligase SKP2 , 2021, Molecular Cancer Research.
[13] Ying-Jie Hu,et al. Lappaol F, an anticancer agent, inhibits YAP via transcriptional and post-translational regulation , 2021, Pharmaceutical biology.
[14] Juan Li,et al. Synergistic Combination of Sodium Aescinate-Stabilized, Polymer-Free, Twin-Like Nanoparticles to Reverse Paclitaxel Resistance , 2020, International journal of nanomedicine.
[15] Jinghang Zhang,et al. Skp2 Depletion Reduces Tumor-Initiating Properties and Promotes Apoptosis in Synovial Sarcoma , 2020, Translational oncology.
[16] D. Zheng,et al. Down-regulation of Skp2 expression inhibits invasion and lung metastasis in osteosarcoma , 2018, Scientific Reports.
[17] J. Prat,et al. Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics. , 2018, Human pathology.
[18] Li Ma,et al. SKP2- and OTUD1-regulated non-proteolytic ubiquitination of YAP promotes YAP nuclear localization and activity , 2018, Nature Communications.
[19] Wen-ying Lee,et al. Panobinostat sensitizes KRAS‐mutant non‐small‐cell lung cancer to gefitinib by targeting TAZ , 2017, International journal of cancer.
[20] D. Lim,et al. Mechanical cue‐induced YAP instructs Skp2‐dependent cell cycle exit and oncogenic signaling , 2017, The EMBO journal.
[21] Chunli Wu,et al. Induction of G2M Arrest by Flavokawain A, a Kava Chalcone, Increases the Responsiveness of HER2-Overexpressing Breast Cancer Cells to Herceptin , 2017, Molecules.
[22] Jing Yang,et al. Epithelial–mesenchymal transition in tumor metastasis , 2016, Molecular oncology.
[23] Jing Wang,et al. Verteporfin can Reverse the Paclitaxel Resistance Induced by YAP Over-Expression in HCT-8/T Cells without Photoactivation through Inhibiting YAP Expression , 2016, Cellular Physiology and Biochemistry.
[24] Valerie M. Weaver,et al. Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors , 2015, Molecular biology of the cell.
[25] D. Mercola,et al. Flavokawain A induces deNEDDylation and Skp2 degradation leading to inhibition of tumorigenesis and cancer progression in the TRAMP transgenic mouse model , 2015, Oncotarget.
[26] J. George,et al. The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene , 2011, Oncogene.
[27] S. Orsulic,et al. Ovarian Cancer , 1993, British Journal of Cancer.
[28] Gui-Bin Xue,et al. Catalpol suppresses osteosarcoma cell proliferation through blocking epithelial-mesenchymal transition (EMT) and inducing apoptosis. , 2018, Biochemical and biophysical research communications.